Abstract
Background Exosomes are small endosome-derived vesicles ranging from 30-120 nm in diameter secreted from cells through exocytosis and, in cancer context, are able to prepare metastasis niche and suppress host’s immune system. Despite these pro-tumorigenic characteristics, exosomes can be useful for several Biotechnological applications such as biological anticancer vaccines, cancer diagnosis and prognosis. Due to its property of carrying parental cell’s protein and active nucleic acids there is an increasing interest to use exosomes to track cancer metabolism alterations in different conditions, for example, during drug administration [1]. One of the most common types of cancer that develops drug resistance during drug treatment is Melanoma. The majority of drugs developed against melanoma targets the oncogenic mutations in BRAF (BRAF V600E) that are present in nearly 60% of cutaneous melanoma tumors. Resistance to BRAFV600E inhibitors are classified in two main groups, Intrinsic Resistance and Acquired Resistance, the second is developed after treatment starts that happens mainly by MAPK reactivation and RTK upregulation [2]. Various methods are being studied to overcome drug resistance in melanoma, but there is a need to detect when the resistant mechanism is arising to orientate which approach to choose. This early detection has demonstrated to be a difficult task especially during advanced stages where there are several metastatic niches. With this aim, our research project was designed to create a method to follow tumor’s status through melanoma-derived exosomes. As most types of melanoma overexpress MART-1 we checked its expression, as well as PDGFR-B and others proteins, in PLX4032 (V600E mutated BRAF inhibitor) resistant and sensitive melanoma cell lines to start to understand their potential to be exosomes-associated proteins in the development of acquired resistance detection method[2].
Highlights
Exosomes are small endosome-derived vesicles ranging from 30-120 nm in diameter secreted from cells through exocytosis and, in cancer context, are able to prepare metastasis niche and suppress host’s immune system
The majority of drugs developed against melanoma targets the oncogenic mutations in BRAF (BRAF V600E) that are present in nearly 60% of cutaneous melanoma tumors
Resistance to BRAFV600E inhibitors are classified in two main groups, Intrinsic Resistance and Acquired Resistance, the second is developed after treatment starts that happens mainly by MAPK reactivation and RTK upregulation [2]
Summary
Exosomes are small endosome-derived vesicles ranging from 30-120 nm in diameter secreted from cells through exocytosis and, in cancer context, are able to prepare metastasis niche and suppress host’s immune system. One of the most common types of cancer that develops drug resistance during drug treatment is Melanoma. The majority of drugs developed against melanoma targets the oncogenic mutations in BRAF (BRAF V600E) that are present in nearly 60% of cutaneous melanoma tumors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.